Presentation is loading. Please wait.

Presentation is loading. Please wait.

Coronary heart disease (CHD) event rates in secondary prevention and acute coronary syndrome trials A. Kumar, C.P. Cannon. Arch Med Sci 2007;3:S115-S125.

Published byJillian Gull Modified over 9 years ago

Similar presentations

Presentation on theme: "Coronary heart disease (CHD) event rates in secondary prevention and acute coronary syndrome trials A. Kumar, C.P. Cannon. Arch Med Sci 2007;3:S115-S125."— Presentation transcript:

1 Coronary heart disease (CHD) event rates in secondary prevention and acute coronary syndrome trials A. Kumar, C.P. Cannon. Arch Med Sci 2007;3:S115-S125

2 Number of ruptured plaques in addition to ruptured lesion in acute coronary syndrome (80% of patients with ≥1 ruptured plaque) A. Kumar, C.P. Cannon. Arch Med Sci 2007;3:S115-S125

3 Integrated approach to managing patients with acute coronary syndrome A. Kumar, C.P. Cannon. Arch Med Sci 2007;3:S115-S125

4 Kaplan-Meier estimates of the incidence of primary endpoint of death from any cause or a major cardiovascular event in PROVE IT-TIMI 22 A. Kumar, C.P. Cannon. Arch Med Sci 2007;3:S115-S125

5 “Pleiotropic” effects of statins in acute coronary syndrome A. Kumar, C.P. Cannon. Arch Med Sci 2007;3:S115-S125

6 Cumulative incidence of recurrent myocardial infarction or death from coronary causes according to the achieved levels of both low density lipoprotein (LDL) cholesterol and C-reactive protein (CRP) in PROVE IT-TIMI 22 A. Kumar, C.P. Cannon. Arch Med Sci 2007;3:S115-S125

7 Relationship between the number of uncontrolled risk factors present and the median C-reactive protein (CRP) level for standard versus intensive statin therapy in PROVE IT-TIMI 22 A. Kumar, C.P. Cannon. Arch Med Sci 2007;3:S115-S125

8 Individual trials and pooled analysis showing a highly significant 16% reduction in the risk of coronary death or myocardial infarction (p<0.0001); CI - confidence interval, OR - odds ratio A. Kumar, C.P. Cannon. Arch Med Sci 2007;3:S115-S125

9 Benefit of intensive statin therapy versus moderate statin therapy in reducing the risk of hospitalization for heart failure in a meta-analysis of 27,546 patients A. Kumar, C.P. Cannon. Arch Med Sci 2007;3:S115-S125

10 Level of low density lipoprotein cholesterol achieved at 4 months and the long-term risk of death or major cardiovascular event A. Kumar, C.P. Cannon. Arch Med Sci 2007;3:S115-S125

11 Risk of major cardiovascular events according to quintile of achieved low density lipoprotein (LDL) cholesterol in Treating to New Targets study A. Kumar, C.P. Cannon. Arch Med Sci 2007;3:S115-S125

12 Recent coronary intravascular ultrasound trials (relationship between mean low density lipoprotein cholesterol level and progression rate of coronary atherosclerosis) A. Kumar, C.P. Cannon. Arch Med Sci 2007;3:S115-S125

Download ppt "Coronary heart disease (CHD) event rates in secondary prevention and acute coronary syndrome trials A. Kumar, C.P. Cannon. Arch Med Sci 2007;3:S115-S125."

Similar presentations

Foos et al, EASD, Lisbon, 13 September 2011 Comparison of ACCORD trial outcomes with outcomes estimated from modelled and meta- analysis studies Volker.

Foos et al, EASD, Lisbon, 13 September 2011 Comparison of ACCORD trial outcomes with outcomes estimated from modelled and meta- analysis studies Volker.
1. 2 The primary Objective of IDEAL LDL-C Simvastatin 20-40 mg/d Atorvastatin 80 mg/d risk CHD In stable CHD patients IDEAL: The Incremental Decrease.

1. 2 The primary Objective of IDEAL LDL-C Simvastatin mg/d Atorvastatin 80 mg/d risk CHD In stable CHD patients IDEAL: The Incremental Decrease.
P H Y S I C I A N S ’ A C A D E M Y F O R C A R D I O V A S C U L A R E D U C A T I O N Insights from clinical trials: The unassailable case for LDL-c.

P H Y S I C I A N S ’ A C A D E M Y F O R C A R D I O V A S C U L A R E D U C A T I O N Insights from clinical trials: The unassailable case for LDL-c.
Lipid Disorders and Management in Diabetes

Lipid Disorders and Management in Diabetes
Trial profile Fox K et al. Lancet 2008;372:807-16.

Trial profile Fox K et al. Lancet 2008;372:
Slide Source: Lipids Online Slide Library www.lipidsonline.org Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE IT): Design Cannon CP.

Slide Source: Lipids Online Slide Library Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE IT): Design Cannon CP.
Prescribing Information is available at the end of this presentation NHS Surrey Lipid Guidelines Dr Adam Jacques Ashford & St.

Prescribing Information is available at the end of this presentation NHS Surrey Lipid Guidelines Dr Adam Jacques Ashford & St.
MIRACL, Val-HeFT, Cheney Clinical Trial Commentary Dr Eric Topol Chairman and Professor, Department of Cardiology Director of the Joseph J Jacobs Center.

MIRACL, Val-HeFT, Cheney Clinical Trial Commentary Dr Eric Topol Chairman and Professor, Department of Cardiology Director of the Joseph J Jacobs Center.
TNT: Study Design Treating to New Targets 2 5 years 10,001 Patients Clinically evident CHD LDL-C 130  250 mg/dL following up to 8-week washout and 8-week.

TNT: Study Design Treating to New Targets 2 5 years 10,001 Patients Clinically evident CHD LDL-C 130  250 mg/dL following up to 8-week washout and 8-week.
The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) The LIPID Study Group N Engl J Med 1998;339:1349-57.

The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) The LIPID Study Group N Engl J Med 1998;339:
Cholesterol quintile (mg/dL)

Cholesterol quintile (mg/dL)
How Aggressive do we get on Lipids? Christopher Cannon, M.D. Senior Investigator, TIMI Study Group Cardiovascular Division, Brigham and Women’s Hospital,

How Aggressive do we get on Lipids? Christopher Cannon, M.D. Senior Investigator, TIMI Study Group Cardiovascular Division, Brigham and Women’s Hospital,
VBWG IDEAL: The Incremental Decrease in End Points Through Aggressive Lipid Lowering Study.

VBWG IDEAL: The Incremental Decrease in End Points Through Aggressive Lipid Lowering Study.
COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)

COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)
Modern Management of Cholesterol in the High-Risk Patient.

Modern Management of Cholesterol in the High-Risk Patient.
10 Points to Remember on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in AdultsTreatment of Blood Cholesterol to Reduce.

10 Points to Remember on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in AdultsTreatment of Blood Cholesterol to Reduce.
1 Statin treatment is associated with improved prognosis in patients with AF-related stroke G. Ntaios, V. Papavasileiou, K.Makaritsis, A.Karagiannaki,

1 Statin treatment is associated with improved prognosis in patients with AF-related stroke G. Ntaios, V. Papavasileiou, K.Makaritsis, A.Karagiannaki,
Laura Mucci, Pharm.D. Candidate Mercer University 2012 Preceptor: Dr. Rahimi February 2012.

Laura Mucci, Pharm.D. Candidate Mercer University 2012 Preceptor: Dr. Rahimi February 2012.
Incremental Decrease in Clinical Endpoints Through Aggressive Lipid Lowering (IDEAL) Trial IDEAL Trial Presented at The American Heart Association Scientific.

Incremental Decrease in Clinical Endpoints Through Aggressive Lipid Lowering (IDEAL) Trial IDEAL Trial Presented at The American Heart Association Scientific.
WOSCOPS: West Of Scotland Coronary Prevention Study Purpose To determine whether pravastatin reduces combined incidence of nonfatal MI and death due to.

WOSCOPS: West Of Scotland Coronary Prevention Study Purpose To determine whether pravastatin reduces combined incidence of nonfatal MI and death due to.

Similar presentations

Ads by Google